logo

For the Inventor, By the Inventor

New York, NY, United States of America

Intercept Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 62

% Expired Patents = 25.8



Trademarks = 8

Forward Citations = 268

Loading Chart...
Loading Chart...

61 inventors (with patents filed for the assignee):

goldMedal Roberto Pellicciari (40 out of 66 patents)

silverMedal Mark Pruzanski (15 out of 15 patents)

bronzeMedal Antimo Gioiello (10 out of 10 patents)

4.  Stefano Fiorucci (8 out of 16 patents)

5.  Emma Sharp (6 out of 11 patents)

6.  Alex Eberlin (6 out of 21 patents)

7.  André Steiner (6 out of 6 patents)

8.  Emilie Jolibois (6 out of 6 patents)

9.  Heidi Waenerlund Poulsen (6 out of 6 patents)

10.  Melissa Rewolinski (6 out of 7 patents)

11.  Ralf Gross (6 out of 6 patents)

12.  Fiona Dubas-Fisher (6 out of 6 patents)

13.  Mitsuhiro Matono (5 out of 8 patents)

14.  Kay Olmstead (4 out of 19 patents)

15.  Gabriel Galvin (4 out of 7 patents)


Core Competencies:
Bile Acid Derivatives
Farnesoid X Receptor
TGR5 Modulators
Obeticholic Acid
Combination Therapy
Cancer Treatment
Fibrosis
Steroid Agonists
Pharmaceutical Compositions
Hepatic Regeneration
Isotopically Labeled Compounds
3-Desoxy Derivative

62 patents:

1. 12337003 - Pharmaceutical compositions for combination therapy (2025-06-24),
2. 12291549 - Farnesoid X receptor modulators (2025-05-06),
3. 11807659 - TGR5 modulators and methods of use thereof (2023-11-07),
4. 11472831 - Isotopically labeled bile acid derivatives (2022-10-18),
5. 11419878 - Medicine obtained by combining FXR agonist and ARB (2022-08-23),
6. 11413295 - Oral preparation of obeticholic acid (2022-08-16),
7. 11345721 - TGR5 modulators and methods of use thereof (2022-05-31),
8. 11319337 - 3-desoxy derivative and pharmaceutical compositions thereof (2022-05-03),
9. 11311557 - Pharmaceutical compositions for combination therapy (2022-04-26),
10. 11072631 - Methods and intermediates for the preparation bile acid derivatives (2021-07-27),
11. 11066437 - Methods and intermediates for the preparation of bile acid derivatives (2021-07-20),
12. 11034717 - Farnesoid X receptor modulators (2021-06-15),
13. 11000532 - Farnesoid x receptor modulators (2021-05-11),
14. 10987362 - Treatment of fibrosis using FXR ligands (2021-04-27),
15. 10894054 - FXR agonist compositions for combination therapy (2021-01-19),
Company Overview
Intercept Pharmaceuticals, Inc., based in New York, NY, specializes in the development of innovative therapies targeting liver diseases. The company focuses on bile acid modulators, particularly through its core technology involving bile acid derivatives and the Farnesoid X receptor. Intercept's research encompasses various therapeutic areas, including fibrosis and cancer treatment, utilizing compounds such as obeticholic acid and TGR5 modulators. Their commitment to advancing combination therapies positions them at the forefront of addressing complex liver conditions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Intercept Pharmaceuticals, Inc. USPTO Patent Assignee Logo
62 Patents

#160 in New York, NY

#348 in New York

#5,849 in US

#11,782 in the World

New York, NY (US)
New York, NY, United States of America

Intercept Pharmaceuticals, Inc.

Forward Citations = 268

61 inventors:

goldMedal Roberto Pellicciari (40 out of 66 patents)

silverMedal Mark Pruzanski (15 out of 15 patents)

bronzeMedal Antimo Gioiello (10 out of 10 patents)

4.  Stefano Fiorucci (8 out of 16 patents)

5.  Emma Sharp (6 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Intercept Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/intercept-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…